Merck (NYSE:MRK) announced Wednesday plans to conduct clinical trials to evaluate the efficacy and safety of a single-dose regimen of its human papillomavirus (HPV) vaccine, Gardasil 9.

Merck (MRK) announced that the National Medical Products Administration of China approved Gardasil Vaccine for use in males 9-26 years of age to help prevent certain HPV-related cancers and diseases.